Leprosy

Abstract

Leprosy is a chronic infectious disease of humans caused by Mycobacterium leprae, in which the skin and peripheral nerves are damaged by chronic inflammation initiated by the cellular immune response to the organism.

Keywords: Mycobacterium leprae; nerves; skin; cellular immunity; infection

Figure 1.

Mechanism of infection of Schwann cells by Mycobacterium leprae. Monocytes carrying M. leprae cross the perineurium in blood vessels and passage through nerves. Leprosy bacilli released from the monocytes bind to the G domain of α2 chain of laminin 2 in the basal lamina surrounding Schwann cells. In turn, M. leprae binds to α‐dystroglycan, and its uptake by Schwann cells is mediated by this and other intracellular proteins. T lymphocytes recognize peptides (*) derived from M. leprae proteins presented by HLA molecules on the surface of infected monocytes and possibly Schwann cells. The lymphocytes release Interferon (IFN) Ð and tumour necrosis factor (TNF) causing inflammatory damage to the nerve. IFN, interferon; TNF, tumour necrosis factor.

Figure 2.

The clinical–immunopathological spectrum of leprosy. Patients at the tuberculoid pole have strong interferon (IFN) γ‐secreting CD4+ T‐cell responses against Mycobacterium leprae and few mycobacteria in affected tissues, whereas patients at the leprosy pole have no measurable T‐cell responses and unrestrained replication of M. leprae.

Figure 3.

The nerves preferentially infected with Mycobacterium leprae. Nerve trunks (in bold) bearing motor and sensory fibres are infected where they traverse close to the surface. Other superficial sensory nerves (in italics) are also infected. Enlargement of any of these nerves with or without loss of function in their distribution is typical of leprosy.

close

References

Britton WJ (1993) Immunology of leprosy. Transactions of the Royal Society of Tropical Medicine and Hygiene 82: 508–514.

Britton WJ (1998) The management of leprosy reversal reactions. Leprosy Review 69: 225–234.

Britton WJ (1999) Leprosy. In: Armstrong D and Cohen J (eds) Infectious Diseases, vol. 6, pp. 1–6. London: Mosby.

Cole S, Eiglmeier K, Parkhill J et al. (2001) Massive gene decay in the leprosy bacillus. Nature 409: 1007–1011.

Gebre S, Saunderson P, Messele T and Byass P (2000) The effect of HIV status on the clinical picture of leprosy: a prospective study in Ethiopia. Leprosy Review 74: 338–343.

Hastings RC (ed.) (1994) Leprosy, 2nd edn. Edinburgh: Churchill Livingstone.

Hill AVS (1998) Immunogenetics of human infectious disease. Annual Review of Immunology 16: 593–618.

Honore N, Perani E, Telenti A et al. (1993) A simple and rapid technique for the detection of rifampicin resistance in Mycobacterium leprae. International Journal of Leprosy and Other Mycobacterial Diseases 61: 600–604.

Joffrion VC (1994) Ocular leprosy. In: Hastings RC (ed.) Leprosy, 2nd edn, pp. 353–366. Edinburgh: Churchill Livingstone.

Karonga Prevention and Trial Group (1996) Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 348: 17–24.

Lockwood DNJ (1996) Management of erythema nodosum: current and future options. Leprosy Review 67: 249–259.

Nordeen SK (1994) Leprosy. In: Rakel RE (ed.) Conn′s Current Therapy, pp. 89–94. Philadelphia, PA: WB Saunders.

Porcelli SA and Modlin RL (1999) Antigen presenting molecules for T cell recognition of lipids and glycolipids. Annual Review of Immunology 17: 297–330.

Rambukkana A, Yamada H, Zanazzi G et al. (1998) Role of alpha‐dystroglycan as a Schwann cell receptor for Mycobacterium leprae. Cell 282: 2076–2079.

Rees RJW and Young DB (1994) The microbiology of leprosy. In: Hastings RC (ed.) Leprosy, 2nd edn, pp. 49–86. Edinburgh: Churchill Livingstone.

Ridley DS and Jopling WH (1966) Classification of leprosy according to immunity. International Journal of Leprosy 34: 255–273.

Srinivasan H (1994) Rehabilitation in leprosy. In: Hastings RC (ed.) Leprosy, 2nd edn, pp. 411–448. Edinburgh: Churchill Livingstone.

World Health Organization (1982) WHO study group on chemotherapy of leprosy for control programmes. World Health Organization Technical Report Series 675.

World Health Organization (1994) WHO study group on chemotherapy of leprosy. World Health Organization Technical Report Series 847.

World Health Organization (1998a) Progress towards the elimination of leprosy as a public health problem. Weekly Epidemiological Record 73: 149–156.

[http://www.who.int/lep/in.htm]

World Health Organization (1998b) Expert committee on leprosy. World Health Organization Technical Report Series 874: 1–43.

Yamamura M, Uyemura K, Deans RJ et al. (1991) Defining protective immune responses to pathogens: cytokine profiles in leprosy lesions. Science 254: 277–279.

Further Reading

Bryceson A and Pfaltzgraff RE (1990) Leprosy, 3rd edn. Edinburgh: Churchill Livingstone.

Deepak S (1995) Leprosy and community‐based rehabilitation. Leprosy Review 66: 273–276.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Britton, Warwick J(May 2002) Leprosy. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1038/npg.els.0002300]